Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Top Cited Papers
- 1 December 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 396 (10265), 1817-1828
- https://doi.org/10.1016/s0140-6736(20)32531-9
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Triple-negative breast cancer: are we making headway at least?Therapeutic Advances in Medical Oncology, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Mechanism of synergistic effect of chemotherapy and immunotherapy of cancerCancer Immunology, Immunotherapy, 2010
- Immune Regulation of CancerJournal of Clinical Oncology, 2010
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast CancerJournal of Clinical Oncology, 2010
- Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial DesignClinical Breast Cancer, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Pattern of metastatic spread in triple-negative breast cancerBreast Cancer Research and Treatment, 2008
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007